Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Added to Nasdaq Biotech Index

NEW YORK (GenomeWeb) — Foundation Medicine said today that the company has been added to the Nasdaq Biotechnology Index. 

The index tracks Nasdaq-listed securities that are classified as either biotechnology or pharmaceutical by the Industry Classification Benchmark. The index, which is reranked each year, is also the basis for the iShares Nasdaq Biotechnology Index Fund. The fund seeks investment results corresponding generally to the price and yield performance of the Nasdaq Biotechnology Index, and options based on the index fund trade on various exchanges. 

A total of 44 firms were added to the index, while eight were removed, including Cellular Dynamics International. 

In morning trading on Tuesday, shares of Foundation Medicine were up a fraction of 1 percent at $21.01. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.